Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), exercised 3,984 stock options with an exercise price of $6.80 per share and immediately sold those 3,984 shares at a weighted average price of $90.0832 on 08/11/2025. The sale was effected pursuant to a Rule 10b5-1 trading instruction adopted on 08/08/2024.
After these transactions, Shulman's reported direct beneficial ownership of common stock declined from 12,493 shares to 8,509 shares. The Form 4 also reports 7,969 stock options outstanding following the transactions.
Rhythm Pharmaceuticals (RYTM) filed a Form 144 reporting a proposed sale of 28,088 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $2,648,979.28. The filing states these shares were acquired the same day by exercise of stock options and paid in cash, indicating an immediate disposition of newly exercised options rather than a transfer from a third party.
The filing does not name the person for whose account the proposed sale is to be made in the main table, though the filing discloses two prior 10b5-1 sales attributed to Hunter Smith totaling 65,520 shares and gross proceeds of $4,826,766.67 in the past three months. The notice includes the standard representation that the signer is not aware of undisclosed material adverse information and references reliance on any Rule 10b5-1 trading plan if applicable.
Christopher Paul German filed a Form 144 reporting a proposed sale of 1,500 Rhythm Pharmaceuticals (RYTM) common shares acquired by exercising stock options on 08/12/2025. The filing shows the shares were paid for in cash, lists Morgan Stanley Smith Barney LLC as broker, assigns an aggregate market value of $141,465.00, and identifies the planned sale on 08/12/2025 on NASDAQ. The issuer has 66,420,091 shares outstanding. The notice also discloses prior 10b5-1 sales by Mr. German in 06/10/2025 and 07/09/2025, totaling 5,886 shares for $447,233.36 gross proceeds. The form includes the standard insider representation about material nonpublic information.
Rhythm Pharmaceuticals (RYTM) reported a Form 144 notice showing an insider transaction involving common stock. The filing discloses the planned sale of 3,984 shares on 08/11/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $366,448.32. Those shares were acquired the same day by exercise of stock options from the issuer and paid for in cash.
The filing also lists shares outstanding of 66,420,091, and prior 10b5-1 sales on 07/09/2025 of 7,969 shares for gross proceeds of $619,850.56. The notice includes the standard officer representation about absence of undisclosed material adverse information.
Form 4 shows Rhythm Pharmaceuticals (RYTM) Chief Human Resources Officer Pamela J. Cramer had two Section 16 transactions.
- 07/26/25 – Code M: 3,125 restricted stock units vested and were converted into common shares. No cash price is listed; RSUs convert 1-for-1.
- 07/29/25 – Code S: 1,520 shares sold at $85.93 per share ($130,614 gross proceeds). The sale was executed under a pre-arranged Rule 10b5-1 plan to cover tax withholdings.
After these transactions, Cramer’s direct ownership increased by a net 1,605 shares to 20,814 shares. The related RSU grant, originally 12,500 units, is now fully vested (25% annually from 2022-2025). No derivative securities remain outstanding.
The activities appear routine for tax-coverage and compensation purposes and represent an immaterial fraction of RYTM’s float, limiting market impact.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
